Ernexa Therapeutics (ERNA) Invested Capital (2016 - 2025)
Historic Invested Capital for Ernexa Therapeutics (ERNA) over the last 16 years, with Q3 2025 value amounting to $3.6 million.
- Ernexa Therapeutics' Invested Capital rose 10892.33% to $3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.6 million, marking a year-over-year increase of 10892.33%. This contributed to the annual value of $1.7 million for FY2024, which is 2382.45% down from last year.
- Latest data reveals that Ernexa Therapeutics reported Invested Capital of $3.6 million as of Q3 2025, which was up 10892.33% from $4.5 million recorded in Q2 2025.
- Ernexa Therapeutics' 5-year Invested Capital high stood at $54.0 million for Q2 2021, and its period low was -$40.5 million during Q3 2024.
- For the 5-year period, Ernexa Therapeutics' Invested Capital averaged around $7.0 million, with its median value being $4.2 million (2023).
- As far as peak fluctuations go, Ernexa Therapeutics' Invested Capital surged by 35928.54% in 2021, and later plummeted by 123607.52% in 2024.
- Quarter analysis of 5 years shows Ernexa Therapeutics' Invested Capital stood at $31.9 million in 2021, then tumbled by 56.62% to $13.9 million in 2022, then plummeted by 83.89% to $2.2 million in 2023, then dropped by 23.82% to $1.7 million in 2024, then soared by 112.29% to $3.6 million in 2025.
- Its Invested Capital was $3.6 million in Q3 2025, compared to $4.5 million in Q2 2025 and -$5.9 million in Q1 2025.